TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
+10.56%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.98B
AUM Growth
+$171M
(+9.4%)
Cap. Flow
+$118M
Cap. Flow
% of AUM
5.98%
Top 10 Holdings %
Top 10 Hldgs %
35.03%
Holding
220
New
18
Increased
34
Reduced
52
Closed
20
Top Buys
| 1 |
Vera Therapeutics
VERA
|
$28.3M |
| 2 |
Merus
MRUS
|
$26.3M |
| 3 |
Mettler-Toledo International
MTD
|
$22.9M |
| 4 |
Boeing
BA
|
$20.9M |
| 5 |
Spyre Therapeutics
SYRE
|
$17.2M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$37.7M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$29M |
| 3 |
SLRN
ACELYRIN
SLRN
|
$24.3M |
| 4 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$10.1M |
| 5 |
CRISPR Therapeutics
CRSP
|
$9.07M |
Sector Composition
| 1 | Healthcare | 94.16% |
| 2 | Technology | 1.37% |
| 3 | Industrials | 1.32% |
| 4 | Communication Services | 1.26% |
| 5 | Consumer Discretionary | 0.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Galapagos
GLPG
$2.2B
| $112M | 5.65% |
3,990,111
+28,314
| +0.7% | +$793K |
|
2
Tarsus Pharmaceuticals
TARS
$2.43B
| $99.4M | 5.03% |
2,454,797
| – | – |
|
3
Aurinia Pharmaceuticals
AUPH
$1.63B
| $84.9M | 4.29% |
10,029,500
| – | – |
|
4
Immunocore
IMCR
$1.87B
| $66.1M | 3.34% |
2,105,608
+189,900
| +10% | +$5.96M |
|
5
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $64.4M | 3.26% |
2,328,609
+210,030
| +10% | +$5.81M |
|
6
Mirum Pharmaceuticals
MIRM
$3.82B
| $62.9M | 3.18% |
1,236,027
-1,080
| -0.1% | -$55K |
|
7
KalVista Pharmaceuticals
KALV
$796M
| $55.9M | 2.82% |
4,941,798
| – | – |
|
8
PTC Therapeutics
PTCT
$4.55B
| $53.7M | 2.72% |
1,100,000
+100,000
| +10% | +$4.88M |
|
|
9
Spyre Therapeutics
SYRE
$1.03B
| $47.9M | 2.42% |
3,200,000
+1,150,000
| +56% | +$17.2M |
|
10
Evolus
EOLS
$495M
| $46M | 2.33% |
4,997,399
| – | – |
|
11
Viridian Therapeutics
VRDN
$1.53B
| $39.7M | 2.01% |
2,842,925
+50,000
| +2% | +$699K |
|
|
ITOS
12
DELISTED
iTeos Therapeutics
ITOS
| $38.2M | 1.93% |
3,826,692
+1,137,492
| +42% | +$11.3M |
|
13
Compass Therapeutics
CMPX
$590M
| $35.1M | 1.77% |
13,496,208
+2,443,576
| +22% | +$6.35M |
|
14
Acadia Pharmaceuticals
ACAD
$4.26B
| $32.4M | 1.64% |
1,500,000
| – | – |
|
|
15
Vera Therapeutics
VERA
$1.54B
| $31.8M | 1.61% |
1,350,000
+1,200,000
| +800% | +$28.3M |
|
|
16
Merus
MRUS
$5.1B
| $31.6M | 1.6% |
600,000
+500,000
| +500% | +$26.3M |
|
17
Replimune Group
REPL
$494M
| $29.7M | 1.5% |
3,200,000
+300,000
| +10% | +$2.79M |
|
18
AnaptysBio
ANAB
$613M
| $29.5M | 1.49% |
1,330,879
-214,274
| -14% | -$4.76M |
|
19
Legend Biotech
LEGN
$6.66B
| $29.5M | 1.49% |
830,000
| – | – |
|
20
BioNTech
BNTX
$27B
| $28.7M | 1.45% |
270,000
| – | – |
|
21
Relay Therapeutics
RLAY
$710M
| $27.9M | 1.41% |
8,068,058
| – | – |
|
|
LENZ
22
LENZ Therapeutics
LENZ
$1.2B
| $26.3M | 1.33% |
897,616
+130,676
| +17% | +$3.83M |
|
23
CytomX Therapeutics
CTMX
$376M
| $25.1M | 1.27% |
11,065,662
+4,347,837
| +65% | +$9.87M |
|
|
24
Mettler-Toledo International
MTD
$26.9B
| $22.9M | 1.16% |
+19,500
| New | +$22.9M |
|
|
25
Boeing
BA
$174B
| $22.1M | 1.12% |
105,662
+99,594
| +1,641% | +$20.9M |
|